RT Journal Article
SR Electronic
T1 [<sup>177</sup>Lu]Lu-PSMA-617 Therapy in a Patient with Chronic Kidney Disease
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1570
OP 1573
DO 10.2967/jnumed.123.265577
VO 64
IS 10
A1 Mercolli, Lorenzo
A1 Mingels, Clemens
A1 Manzini, Giulia
A1 Cumming, Paul
A1 Zeimpekis, Konstantinos
A1 Xue, Song
A1 Alberts, Ian
A1 Uehlinger, Dominik
A1 Rominger, Axel
A1 Shi, Kuangyu
A1 Afshar-Oromieh, Ali
YR 2023
UL http://jnm.snmjournals.org/content/64/10/1570.abstract
AB We report the dosimetric evaluation of prostate-specific membrane antigen–based radioligand therapy (RLT) for metastatic prostate cancer in a patient with autosomal-dominant polycystic kidney disease. Methods: The patient received hemodialysis during each of 6 RLT cycles while staying as an inpatient. We used voxel dosimetry and blood sampling for the dose calculation. Results: The patient responded well to the RLT, as indicated by the prostate-specific antigen level decreasing from 298 to 7.1 ng/mL. The doses per cycle ranged from 0.19 to 0.4 Gy/GBq for the parotid gland, 0.14 to 0.28 Gy/GBq for the submandibular gland, 0.03 to 0.11 Gy/GBq per kidney, and 0.10 to 0.15 Gy/GBq for the red bone marrow. Conclusion: This case suggests that [177Lu]Lu-PSMA–based RLT can be applied successfully and safely to a patient with chronic kidney disease undergoing hemodialysis.